Skip to content

To Compare The Efficacy Of Nebulized Dexmedetomidine Versus Normal Saline For Patients Comfort And Satisfaction During Diagnostic Upper Gastrointestinal Endoscopy

Efficacy Of Nebulized Dexmedetomidine For Patients Comfort And Satisfaction During Diagnostic Upper Gastrointestinal Endoscopy - Nil

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/09/073834
Enrollment
64
Registered
2024-09-12
Start date
Unknown
Completion date
Unknown
Last updated
2024-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O- Medical and Surgical

Interventions

Intervention1: Dexmedetomidate: nebulised dexmedetomidine 1mcg/kg diluted in normal saline (0.9%) to a volume of 5ml given prior to procedure. Control Intervention1: Normal saline: nebulized normal sa

Sponsors

Dr Reshma salim
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients aged between 18 to 70 years of either sex 2. American Society of Anaesthesiology (ASA) grade I and II posted for elective diagnostic upper gastrointestinal endoscopy.

Exclusion criteria

Exclusion criteria: 1) Patients with uncontrolled hypertension/hypotension 2) Psychiatricillness 3) Not willing

Design outcomes

Primary

MeasureTime frame
To evaluate nebulized dexmedetomidine vs nebulized normal saline for patients comfort and satisfaction during diagnostic upper gastrointestinal endoscopy.Timepoint: will be assesed at baseline,post nebulisation,during procedure,post procedure .

Secondary

MeasureTime frame
Stress response to upper gastrointestinal endoscopy Ease of procedure by endoscopist Patients comfort & satisfaction Side effects of study drug if anyTimepoint: will be assessed during & post procedure on the same day itself of the surgery.

Countries

India

Contacts

Public ContactDr Bhavini Shah

Dr DY Patil Medical College hospital and research centre,pimpri pune

drbhavinishah71@gmail.com8547835546

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026